| Insider · 14 positions | Net Shares per Quarter (+ Bought / − Sold) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Role | Shares Held ↓ | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
| Hunter C Smith | Chief Financial Officer | 120K | — | — | -8K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Yann Mazabraud | EVP, Head of International | 113K | -57K | — | +35K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Jennifer Kayden Lee | EVP, Head of North America | 76K | -76K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Manher Joshi | Chief Medical Officer | 50K | +75K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Joseph Shulman | Chief Technical Officer | 21K | -5K | — | +38K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Edward T Mathers | — | 14K | — | — | +8K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Kimberly J Popovits | 10K | — | +17K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Alastair Garfield | Chief Scientific Officer | 8K | -10K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Christopher Paul German | Corporate Controller & CAO | 5K | — | -5K | -6K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Christophe Jean | 4K | — | +6K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| David W J Mcgirr | 4K | — | +6K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Lynn A. Tetrault | 4K | — | -31K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Stuart A Arbuckle | 4K | — | +6K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Jennifer L Good | 4K | — | +6K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |